Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
    • Publication Information:
      Publication: [Philadelphia, PA] : Taylor & Francis
      Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989-
    • Subject Terms:
      Hematopoietic Stem Cell Transplantation/*methods ; Lymphoma/*therapy; Adolescent ; Adult ; Disease-Free Survival ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Male ; Middle Aged ; Prognosis ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
    • Abstract:
      The present study aimed to investigate baseline and posttransplant prognostic factors for allogeneic hematopoietic cell transplantation (HCT) in 61 lymphoma patients. The 5-year probabilities of overall survival (OS), non-relapse mortality (NRM), progression-free survival (PFS), and event-free survival (EFS) were 31.1%, 28.8%, 38.8%, and 23.2%, respectively. Multivariate analysis demonstrated that the International Prognostic Index risk at HCT was a significantly independent prognostic factor for OS, NRM, PFS, and EFS, and chemosensitivity was a prognostic factor for OS, NRM, and EFS. The occurrence of chronic graft-versus-host disease (GVHD) was significantly associated with higher OS, but it was not with PFS or EFS. Various parameters of immune reconstitution at 1 month after transplantation were associated with clinical outcomes in different ways. Our study results might be helpful in selecting appropriate patients or adopting effective posttransplant treatment strategies, eventually leading to an improvement in outcomes after allogeneic HCT for lymphoma.
    • Contributed Indexing:
      Keywords: GVHD; IPI; Lymphoma; allogeneic HCT; chemosensitivity; immune reconstitution
    • Publication Date:
      Date Created: 20171123 Date Completed: 20190207 Latest Revision: 20190215
    • Publication Date:
      20221213
    • Accession Number:
      10.1080/10428194.2017.1399310
    • Accession Number:
      29164971